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HeartComparative study of cardio protective effect of aliskiren, telmisartan, and torsemide was car-
ried out on L-nitro arginine methyl ester (L-NAME) induced hypertension in rats. The three
drugs were given daily for 8 weeks simultaneously with L-NAME, with a control group for each
drug and L-NAME. The degree of protection was assessed by measurement of systolic blood
pressure and heart rate of animals every two weeks. At the end of the experimental period blood
sampling was carried out for estimation of the level of NO2
/NO3
. After which animals were
sacriﬁced for heart dissection to detect collagen types I and III gene expression. Histopatholo-
gical study was done to evaluate the extension of collagen deposits. The study revealed that the
three drugs decreased blood pressure signiﬁcantly compared to L-NAME. There was no signif-
icant difference between aliskiren and telmisartan in all measurements, but there was signiﬁcant
decrease in measurements of both aliskiren and telmisartan treated groups compared to tor-
semide starting from 4th week. There were insigniﬁcant changes in pulse rate values between
the three L-NAME treated groups through the experiment. The three drugs signiﬁcantly
increased NO compared to L-NAME. Collagen I and III gene expression was signiﬁcantly
decreased by the three drugs but the highest percentage of inhibition was with telmisartan com-
pared to L-NAME. Comparing the percentage inhibition of cardiac ﬁbrosis, there was insignif-
icant difference between telmisartan and torsemide treated groups while both were superior to
aliskiren. In conclusion, further experimental studies are required to elucidate the potential
cardioprotective mechanisms of aliskiren, telmisartan and torsemide, and assess their efﬁcacy
in treatment of heart failure.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Arterial hypertension induces numerous alterations in the
composition of cardiac tissue, which, in turn, results in struc-
tural remodeling of the myocardium. One of these processes
involves disruption of the equilibrium between the synthesis
and degradation of type-I and type-III collagen molecules.
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gen ﬁbers in interstitial and perivascular spaces which contrib-
utes to the development of cardiac complications in
hypertensive patient so-called hypertensive heart disease [1].
The endothelium has a central role in the regulation of
blood pressure and ﬂow through modulation of vascular tone
[2]. Endothelial dysfunction is primarily characterized by
impaired regulation of vascular tone as a result of reduced
endothelial nitric oxide synthase activity, lack of cofactors
for nitric oxide synthesis, attenuated nitric oxide release, or
increased nitric oxide degradation [3].
The renin-angiotensin-aldosterone system (RAAS) plays an
important role in the pathogenesis of a variety of clinical con-
ditions, including atherosclerosis, hypertension, left ventricular
hypertrophy, myocardial infarction, and heart failure. As a
result, the RAAS represents a logical therapeutic target in
the management of hypertension, renal disease, and cardiovas-
cular disease [4]. Pharmacological agents that block the RAAS
include angiotensin-converting enzyme inhibitors (ACEIs),
angiotensin receptor blockers (ARBs), and mineralocorticoid
receptor antagonists (MRAs) and have become the corner-
stones of antihypertensive therapy in high-risk patients [5].
There has been increased emphasis on studying the effect of
direct renin inhibitors (DRIs), agents that block RAAS at its
point of activation, either alone or in combination with other
RAAS-blocking agents [6].
Aliskiren is an orally active, non-peptide DRI that binds to
a pocket in the renin molecule, blocking its interaction with
angiotensinogen and preventing its cleavage to angiotensin I
[7]. Unlike other agents that block the RAAS, DRIs lead to
a decrease in pro-renin activation and all other downstream
components of the RAAS [8]. It has also been reported that
telmisartan (ARB) induced a signiﬁcant increases of angioten-
sin converting enzyme-2 (ACE-2) gene and protein expressions
in the myocardium of pressure-overloaded rats and also atten-
uates vascular hypertrophy in spontaneously hypertensive rats
by the modulation of ACE-2 expression with a marked rever-
sal of extracellular-signal regulated kinase 1/2 (ERK1/2) and c-
Jun N-terminal kinase (JNK) phosphorylation signaling path-
ways. Collectively, these results suggest that angiotensin–(1–7)
causes vasodilation, which antagonizes angiotensin II type 1
receptor (AT1R) mediated vasoconstriction, thereby resulting
in a blood-pressure-lowering effect, reduction of cardiac
hypertrophy and ﬁbrosis and renal damage [9].
Loop diuretics such as torsemide are currently recom-
mended by the European Society of Cardiology in the treat-
ment of congestive heart failure (CHF) and hypertension
[10]. Unlike furosemide, it is noteworthy that torsemide is able
to inhibit the adrenal secretion of aldosterone and its bonding
to mineralocorticoid receptor as well as decreasing transcardi-
ac extraction of aldosterone in CHF patients. Based on this, it
could be hypothesized that its effects on cardiac ﬁbrosis occur
by inhibiting the proﬁbrotic actions of aldosterone [11].
In the present study dose dependent hypertension in rats is
induced via chronic blockade of nitric oxide (NO) by the
administration of L-nitro arginine methyl ester (L-NAME).
We aim to demonstrate the effect L-NAME on blood pressure,
heart rate, serum nitric oxide and collagen type I and III gene
expression and ﬁbrosis in cardiac tissue in rats, to clarify and
compare the modulating effects of aliskiren, telmisartan and
torsemide on the same factors in L-NAME challenged rats.Material and methods
Drugs and chemicals
We utilized Nx-Nitro-L-arginine methyl ester hydrochloride
(L-NAME; Sigma chemical company) obtained as white crys-
talline powder and freshly prepared, Tekturna tablets (Novar-
tis. America; aliskiren 150 mg), Micardis tablets (Boehringer
Ingelheim, Germany; telmisartan 40 mg) and Torseretic tablets
(Medizen pharmaceutical industries, Egypt; torsemide 20 mg).
Tablets were crushed then dissolved in distilled water.
Animals
48 male Albino Sprague–Dawley strain rats were used of
weights ranging from 200 to 250 g. They were housed in the
animal house of Research Institute of Ophthalmology, each
in a cage, at ordinary room temperature, exposed to
natural daily light–dark cycles and fed with standard
laboratory diet and free access to water. All animals’ proce-
dures were performed in accordance with the Institutional Ethics
Committee.
Experimental design
Animals were randomly divided into three main groups:
Group I: Control group, consists of four subgroups of 6 rats
each.
 Normal control: Rats received 1 mL distilled water.
 Aliskiren control: Rats received simultaneous aliskiren 30 -
mg/kg + 1 mL distilled water.
 Telmisartan control: Rats received simultaneous telmisartan
10 mg/kg/day + 1 mL distilled water.
 Torsemide control: Rats received simultaneous torsemide
0.2 mg/kg every 12 h + 1 mL distilled water. All groups r-
eceived drugs daily orally for 8 weeks.
Group II: L-NAME group (6 rats): Rats received L-NAME
50 mg/kg per day + 1 mL distilled water daily orally for
8 weeks.
Group III: Treated group, consists of three subgroups of 6
rats each.
 L-NAME+ Aliskiren treated group.
 L-NAME+ Telmisartan treated group.
 L-NAME+ Torsemide treated group. Rats received drugs
as mentioned before.
Assessments
Blood pressure measurement
Systolic blood pressure and heart rate of animals were mea-
sured every two weeks by noninvasive blood pressure monitor
(ML 125 NIBP, AD Instruments, Australia) from the tail of
conscious rats by the tail-cuff technique. The average of at
least three blood pressure measurements was taken at each
occasion. Heart rate was recorded automatically by a counter
triggered by the pulse wave.
Effect of aliskiren, telmisartan, and torsemide on cardiac dysfunction in hypertensive rats 969Determination of nitric oxide
At the end of the experimental period blood samples were
withdrawn from the retro-orbital vein of each animal under
light anesthesia, and collected in non-heparinized tubes. The
separated serum was used for estimation of the level of
NO2
/NO3
. After that animals were sacriﬁced for heart dissec-
tion to detect collagen type I and III gene expression and for
histopathological study. Nitric oxide was determined in serum
according to the method of El-Mosallamy et al. [12].
Detection of collagen type I and III gene expression by
Quantitative Real Time PCR. Total RNA was extracted from
heart tissue using SV Total RNA Isolation system (Promega,
Madison, WI, USA). The cDNA master mix was prepared
according to the kit and was added (19 ll for each sample)
to the 13 ll RNA-primer mixture. The last mixture was incu-
bated in the programmed thermal cycler. Then RNA was
changed into c DNA. The gene-speciﬁc forward and reverse
primer pair was normalized. Each primer (forward and
reverse) concentration in the mixture was 5 pmol/ll. At the
end of a qPCR running with SYBR Green chemistry, the rel-
ative quantiﬁcation was used according to step one + applied
biosystem software.
Sequence of the primers used for real-time PCR
Collagen type 1 F: 50-TGACCAGCCTCGCTCACAG-30
R: 50-5 GCGGGCAGGGTTCTTTCTA-30
Collagen type 3 F: 50-TCCCAGAACATTACATACCACT-30
R: 50-GCTATTTCCTTCAGCCTTGA-30Histopathology
Formalin ﬁxed, parafﬁn embedded sections of 5 lm thick were
obtained from the ventricle and stained with Hematoxylin &
Eosin and collagen-speciﬁc stain Masson’s trichrome to evalu-
ate the extension of ﬁbrosis and collagen deposits. Collagen
volume fraction (CVF) was calculated by dividing the area
of collagen ﬁbrils by the sum total area of collagen ﬁbrils
and myocardium (reported as the average of 16 ﬁelds). The
degree of ﬁbrosis was graded on a scale of 0–4. Grade 0 signi-
ﬁed no collagen deposits except for small islets around the cap-
illaries, and intercellular single layer of collagenous tissue of
normal myocardium. Focal and minimal ﬁbrosis was graded
as 1 (65%), mild patchy ﬁbrosis as grade 2 (>5% but
<15%), moderate diffuse ﬁbrosis as grade 3 (>15% but
<40%), and prominent ﬁbrosis was classiﬁed as 4 (P40%).
Statistical methods
Using SPSS version 15, data were summarized as:
Mean ± standard deviation (mean ± SD). Comparisons
between groups were done using Analysis of Variance
(ANOVA) and post hoc test. P-values less than 0.05 were con-
sidered statistically signiﬁcant.
Results
The mean systolic blood pressures of the normal control
group, aliskiren, telmisartan and torsemide control groups
were calculated at zero time, 2nd week, 4th week, 6th weekand 8th week respectively and illustrated in Table 1. There
were non-signiﬁcant (P> 0.05) differences between aliskiren,
telmisartan and torsemide control group readings of mean sys-
tolic blood pressure and non-signiﬁcant (P> 0.05) difference
between them compared to normal control group.
Administration of L-NAME increased the systolic blood
pressure signiﬁcantly starting from the 2nd week compared
to normal control group. There was signiﬁcant increase at
any week compared to the preceding one (Table 1). There
was signiﬁcant (P< 0.05) increase in the mean systolic blood
pressure of L-NAME group compared to aliskiren, telmisartan
and torsemide control groups.
The mean systolic blood pressure values of aliskiren, telmi-
sartan and torsemide treated groups were recorded at zero
time, 2nd week, 4th week, 6th week and 8th week respectively
as illustrated in Table 1. There was signiﬁcant (P< 0.05)
decrease in aliskiren and telmisartan treated groups compared
to L-NAME group in the four readings from the 2nd week to
the 8th week, while in torsemide treated group there was signif-
icant (P< 0.05) decrease in 4th week to the 8th week.
There were non-signiﬁcant (P> 0.05) changes in mean sys-
tolic blood pressure values between aliskiren, telmisartan and
torsemide treated groups at the 2nd week. On the other hand
there was signiﬁcant (P< 0.05) decrease in the mean systolic
blood pressure values of both aliskiren and telmisartan treated
groups compared to torsemide treated group at the 4th to 8th
week. However there were non-signiﬁcant (P> 0.05) differ-
ences between aliskiren and telmisartan treated groups in all
readings.
Comparing the mean systolic blood pressure of aliskiren,
telmisartan and torsemide treated groups throughout the
experiment, there was signiﬁcant (P< 0.05) increase at the
2nd week reading compared to that at zero time. The mean
systolic blood pressure values at the 4th week were non-signif-
icantly different from that at the 2nd week. At the 6th week the
mean systolic blood pressure readings were signiﬁcantly
decreased in torsemide group compared to that of the 4th week
reading. On the other hand, there was non-signiﬁcant change
in aliskiren and telmisartan treated groups. There were non-
signiﬁcant (P> 0.05) differences between the 8th and 6th
week systolic blood pressure measurements of the three L-
NAME treated groups.
The mean pulse rates of the normal control group, aliski-
ren, telmisartan, and torsemide control groups were calculated
and illustrated in Table 1. There were non-signiﬁcant
(P> 0.05) differences between aliskiren, telmisartan and tor-
semide control group readings of mean pulse rate throughout
the experiment and non-signiﬁcant (P> 0.05) difference
between all control groups compared to normal control group.
Administration of L-NAME decreased the pulse rate start-
ing from the 2nd week till the end of the experiment as illus-
trated in Table 1. Comparing the change in pulse rate for L-
NAME group there was signiﬁcant decrease (P< 0.05) at
2nd week reading compared to zero time and at 4th week com-
pared to the 2nd week. After that there was non-signiﬁcant
(P> 0.05) decrease in pulse.
There was signiﬁcant (P< 0.05) increase in the pulse rate
values of aliskiren, telmisartan and torsemide treated groups
compared to L-NAME group in the 6th week and the 8th week
readings only. There were non-signiﬁcant (P> 0.05) changes
in pulse rate values between the three L-NAME treated groups
all through the experiment.
Table 1 Mean changes in systolic blood pressure and pulse rate (n= 6).
Groups Time
Zero 2 weeks 4 weeks 6 weeks 8 weeks
Systolic blood pressure (mmHg) (mean ± SD)
Controls Normal 101.72 ± 6.53 102.64 ± 6.83 99.26 ± 5.19 102.60 ± 2.55 103.24 ± 4.05
Aliskiren 102.71 ± 4.03 102.84 ± 3.89 101.88 ± 7.38 101.99 ± 10.34 102.94 ± 7.83
Telmisartan 101.01 ± 8.27 101.05 ± 8.67 102.41 ± 4.48 99.55 ± 8.01 103.13 ± 6.35
Torsemide 101.92 ± 7.55 101.73 ± 6.95 102.77 ± 7.35 100.88 ± 9.56 102.23 ± 15.41
L-NAME 100.70 ± 6.76 129.47 ± 2.25* 139.87 ± 3.71*B 159.17 ± 5.97*,c 171.36 ± 2.78*,1
+26.2% +40.9% +55.1% +65.9%
L-NAME+ aliskiren treated group 102.73 ± 4.29 119.37 ± 2.25n,a 116.37 ± 3.55n,D 112.34 ± 3.65n,D 108.29 ± 5.87n,D
7.8% 16.8% 29.42% 36.81%
L-NAME+ telmisartan treated group 101.19 ± 6.47 120.82 ± 5.88n,a 117.17 ± 5.70n,D 111.62 ± 5.16n,D 107.02 ± 2.39n,D
6.7% 16.2% 29.88% 37.55%
L-NAME+ torsemide treated group 100.16 ± 8.70 124.66 ± 9.93a 130.37 ± 2.53n 120.33 ± 5.02n,c 118.61 ± 4.63n
3.7% 6.8% 24.39% 30.78%
Pulse rate (beats/min) (mean ± SD)
Controls Normal 307 ± 17 310 ± 8 308 ± 10 310 ± 1 308 ± 16
Aliskiren 311 ± 11 310 ± 18 316 ± 16 315 ± 13 310 ± 23
Telmisartan 305 ± 23 309 ± 12 314 ± 25 313 ± 11 310 ± 15
Torsemide 313 ± 7 312 ± 10 316 ± 41 315 ± 5 309 ± 10
L-NAME 312 ± 6 292 ± 11*,a 282 ± 7*,B 289 ± 3* 286 ± 8*
5.9% 8.2% 6.9% 7.3%
L-NAME+ aliskiren treated group 306 ± 24 302 ± 6 303 ± 11 302 ± 9n 305 ± 7n
+3.6% +7.3% +4.5% +6.7%
L-NAME+ torsemide treated group 311 ± 22 300 ± 10 303 ± 8 303 ± 14n 307 ± 7n
+2.9% +7.3% +4.9% +7.5%
* Signiﬁcant at P< 0.05 compared L-NAME group to normal, aliskiren, telmisartan and torsemide control groups.n Signiﬁcant at P< 0.05
compared treated groups to L-NAME group.
D Signiﬁcant at P< 0.05 compared L-NAME with either aliskiren or telmisartan to L-NAME+ torsemide treated group.
a Signiﬁcant at P< 0.05 compared % changes of results at 2 weeks to that at zero time.
B Signiﬁcant at P< 0.05 compared % changes of results at 4 weeks to that at 2 weeks.
c Signiﬁcant at P< 0.05 compared % changes of results at 6 weeks to that at 4 weeks.
1 Signiﬁcant at P< 0.05 compared % changes of results at 8 weeks to that at 6 weeks.
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expression in normal control group was 0.11 ± 0.03. In aliski-
ren, telmisartan, and torsemide control groups, collagen I was
0.10 ± 0.05, 0.09 ± 0.03 and 0.10 ± 0.04 respectively. There
was insigniﬁcant (P> 0.05) difference between aliskiren, tel-
misartan and torsemide control groups compared to normal
control group. On the other hand there was signiﬁcant
(P< 0.05) increase in L-NAME group compared to control
groups as collagen I was 1.8 ± 0.16 (Fig. 1). Collagen I signif-
icantly decreased in the three treated groups compared to L-
NAME group as it was 0.24 ± 0.09, 0.17 ± 0.06 and
0.28 ± 0.04 in aliskiren, telmisartan and torsemide treated
groups respectively. There were non-signiﬁcant (P> 0.05) dif-
ferences between torsemide and telmisartan treated groups
compared to aliskiren treated group. However there was signif-
icant decrease in telmisartan treated group compared to tor-
semide treated group (Fig. 1).
Collagen III gene expression in normal control group was
0.05 ± 0.03 while it was 0.06 ± 0.03, 0.06 ± 0.03 and
0.05 ± 0.03 in aliskiren, telmisartan, and torsemide control
groups, respectively. There were non-signiﬁcant (P> 0.05)
differences between aliskiren, telmisartan, and torsemide con-
trol groups compared to normal control group. Collagen III
in L-NAME group was 1.04 ± 0.12 which was signiﬁcantly
(P< 0.05) increased compared to control groups (Fig. 1). Inaliskiren, telmisartan and torsemide treated groups, collagen
III was 0.16 ± 0.06, 0.09 ± 0.02 and 0.15 ± 0.06 respectively.
There was signiﬁcant (P< 0.05) decrease in collagen III of the
three treated groups compared to L-NAME group. There was
non-signiﬁcant (P> 0.05) difference between either aliskiren
or telmisartan treated groups and torsemide treated group.
However there was signiﬁcant increase in aliskiren treated
group compared to telmisartan treated group.
Serum Nitrite level in normal control group was
1.15 ± 0.12 lM/ml, while in aliskiren, telmisartan and tor-
semide control groups was 1.15 ± 0.19, 1.11 ± 0.15 and
1.15 ± 0.17 lM/ml respectively. There was non-signiﬁcant
(P> 0.05) difference between aliskiren, telmisartan and tor-
semide control groups and normal control group. On the other
hand there was signiﬁcant (P< 0.05) decrease in L-NAME
group compared to control groups as nitrite was
0.19 ± 0.07 lM/ml. Nitrite in aliskiren, telmisartan and tor-
semide treated groups were 0.67 ± 0.05, 0.77 ± 0.09, and
0.73 ± 0.05 lM/ml, respectively. There was signiﬁcant
(P< 0.05) increase in nitrite of the three treated groups com-
pared to L-NAME group. Meanwhile there was non-signiﬁcant
(P> 0.05) difference between aliskiren, telmisartan and tor-
semide treated groups (Fig. 2).
Histopathological examination revealed no abnormal
microscopy for the cardiac muscles of all four control groups.
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Fig. 1 Graph of collagen I & III expression in all groups. *Signiﬁcant at P< 0.05 compared L-NAME group to normal, aliskiren,
telmisartan and torsemide control groups. nSigniﬁcant at P< 0.05 compared aliskiren, telmisartan and torsemide treated groups to
L-NAME group.
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Fig. 2 Graph of mean changes in nitrite in all groups. *Signiﬁcant at P< 0.05 compared L-NAME group to normal, aliskiren,
telmisartan and torsemide control groups. nSigniﬁcant at P< 0.05 compared aliskiren, telmisartan and torsemide treated groups to L-
NAME group.
Fig. 3 Photo (a): section in the cardiac muscle of L-NAME group showing interstitial ﬁbrosis with congestion and few inﬂammatory
cells. (Masson’s trichrome 400·). Photo (b): section in the cardiac muscle of L-NAME+ torsemide group showing interstitial ﬁbrosis,
nuclear pyknosis with internalization, focal congestion and fatty inﬁltration (H&E 400·).
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degenerated with interstitial and perivascular ﬁbrosis, nuclear
pyknosis with internalization, focal sinusoidal venous conges-
tion and fatty inﬁltration. Fibrosis and congestion were mark-
edly decreased in telmisartan and torsemide treated groups
while moderately decreased in aliskiren treated group (Fig. 3).
L-NAME group showed the highest histopathological
grade (3) for interstitial ﬁbrosis among all studied groups aspercentage of ﬁbrosis was 16.7 ± 4.08% and percentage
change from normal was 17%. Telmisartan treated group
showed the lowest histopathological grade (1) for interstitial
ﬁbrosis; 2.2 ± 0.22% and percentage inhibition of ﬁbrosis
compared to L-NAME group was 87%. Torsemide treated
group also showed a histopathological grade (1) for interstitial
ﬁbrosis; 2.5 ± 0.31% and percentage inhibition of ﬁbrosis
compared to L-NAME group was 85%. Aliskiren treated
972 S.A. Sadek et al.group showed a histopathological grade (2) for interstitial
ﬁbrosis; 10 ± 2.07% and percentage inhibition of ﬁbrosis
compared to L-NAME group was 40% (Fig. 3).
Comparing the percentage inhibition of ﬁbrosis between the
three L-NAME treated groups, there was non-signiﬁcant
(P> 0.05) difference between telmisartan and torsemide trea-
ted groups while both are signiﬁcantly higher than aliskiren
treated group.Discussion
In the present study L-NAME induced a time-dependent sig-
niﬁcant elevation of systolic blood pressure, signiﬁcant
decrease of pulse rate, signiﬁcant decrease in serum nitric oxide
metabolites and signiﬁcant increase in collagen I and III genes
expression in the hearts along with the highest histopatholo-
gical grade (3) for interstitial ﬁbrosis among all studied groups.
The data of the present study are in accordance with the ﬁnd-
ings of Gonzalez et al. [13] who found in addition decrease in
cGMP content of the arterial wall, and with El-kharashi et al.
[14] and El-Mosallamy et al. [12].
The chronic depletion of nitric oxide and the arterial hyper-
tension may cause vasoconstriction and hypoperfusion of tis-
sue with the consequent exacerbation of reactive oxygen
species formation [15] associated with an increase in the
renin-angiotensin system activity [16], induces the endothelial
synthesis of the vasoconstrictor prostaglandin (PG 8-iso-
PGF2a) which binds to thromboxane (TXA2) receptor on vas-
cular smooth muscle cells that acts as a potent vasoconstrictor
[17], thereby promoting ischemia and contributing indirectly to
cardiomyocyte hypertrophy and necrosis [18]. The decreased
heart rate with L-NAME administration is in accordance with
a study of Tomida et al. [17]. On the other hand, Nguelefack-
Mbuyo et al. [16] reported that chronic administration of L-
NAME did not alter the heart rate.
The interstitial ﬁbrosis caused by L-NAME in the present
work coincides with the ﬁndings of Rossi and Colombini-
Netto [19] and Hu et al. [20]. Low zinc levels in the myocar-
dium of the L-NAME treated animals have been associated
with reduced antioxidant capacity, increased superoxide gener-
ation, and peroxide accumulation, all of which are known to
damage the myocardium [21]. The ﬁndings of increased expres-
sion of types I and III of collagen genes in L-NAME induced
hypertensive rats when compared with normotensive ones,
are in harmony with the results of Kobayashi et al. [22] and
Zambrano et al. [23].
Data of the present study showed a cardio protective effect
of aliskiren in L-NAME treated rats as evident by signiﬁcant
decrease in systolic blood pressure and signiﬁcant increase in
serum nitric oxide metabolites by a percentage of 252%; com-
pared to L-NAME group. Collagen I and III genes expression
was signiﬁcantly decreased by aliskiren compared to L-NAME
group as the percentage decrease were 86.5% and 84.3% for
collagen I and III respectively. The percentage inhibition of
ﬁbrosis in aliskiren treated group compared to L-NAME group
was 40%.
These results are comparable to the ﬁndings of Wood et al.
[24] who approved that aliskiren shows antihypertensive efﬁ-
cacy in animals, superior to previous renin inhibitors (remiki-
ren and zankiren) and at least equivalent to angiotensin-
converting enzyme inhibitors and angiotensin II type 1 recep-tor blockers. Rakusˇan et al. [25] reported that both aliskiren
and losartan fully prevented the development of hypertension
and cardiac hypertrophy in heterozygous Ren-2 TGR. After
cessation of aliskiren treatment, blood pressure and cardiac
hypertrophy were persistently reduced, while after losartan
withdrawal they rapidly increased. These results coincide with
the ﬁndings of Sun et al. [26], who approved that aliskiren sig-
niﬁcantly reduced the deposition of interstitial collagen I in
ischemic kidneys. Whaley-Connell et al. [27] utilized the trans-
genic Ren2 rat and found that either renin inhibition or angio-
tensin II type 1 receptor (AT1R) blockade, or in combination,
improved to a similar extent left ventricular proﬁbrotic and
growth factors, oxidative stress and associated interstitial
ﬁbrosis, and hypertrophy. On the contrary, in a study of Lu
et al. [28] a lower dose (2.5 mg/kg) of aliskiren did not produce
a signiﬁcant reduction in blood pressure but reduced athero-
sclerotic lesion size in hypercholesterolemia mice.
Aliskiren increases endothelial calcium-dependent nitric
oxide synthase (eNOS) mRNA stability, enhances eNOS phos-
phorylation, decreases NADPH oxidase expression as well as
vascular superoxide and peroxynitrite levels, augments vascu-
lar tetrahydrobiopterin (BH4) levels, and restores eNOS
uncoupling [29]. Aliskiren is more effective in preventing car-
diac ﬁbrosis and suppressing ischemia-mediated activation of
inﬂammation signaling [30]. Rusai et al. [31] found that aliski-
ren increases angiopoietin-1/angiopoietin-2 ratio, promoting
stabilization of endothelial cells, favors pro-angiogenic action
and consequently higher capillary density. Thus we conclude
that renin inhibition might prove to be effective in blocking
the renin angiotensin system compared with existing drugs
and thus be an effective approach to the treatment of hyperten-
sion, alone or in combination with other antihypertensive
drugs.
Data of the present study showed that telmisartan signiﬁ-
cantly decreased systolic blood pressure compared to L-NAME
group. Telmisartan induced signiﬁcant increase in serum nitric
oxide metabolites and signiﬁcant decrease of collagen I and III
genes expression compared to L-NAME group. The percentage
increase in NO is 305% while the percentage decrease of colla-
gen I and III were 90.7% and 91.1% respectively. Telmisartan
improved histopathological grade for cardiac ﬁbrosis as the
percentage inhibition of ﬁbrosis in telmisartan treated group
compared to L-NAME group was 87%.
Casellas et al. [32] approved that candesartan prevented L-
NAME exacerbated hypertension and associated cardio-renal
injury; the beneﬁcial effects exceed those of hydralazine. Wie-
nen and Schierok [33] found that telmisartan/HCTZ combina-
tion produced the greatest reductions in DBP and SBP in
SHRs. Telmisartan monotherapy also decreased DBP and
SBP but only minor BP ﬂuctuations occurred with HCTZ.
The changes in heart rate among SHRs receiving telmisartan
did not differ signiﬁcantly from those receiving vehicle.
The angiotensin II AT1 receptor antagonism as by telmisar-
tan enhances basal NO availability in SHRs [34] and is efﬁcient
in reducing the SHR myocardial ﬁbrosis [35]. Fukushima et al.
[36] investigated Dahl salt-sensitive hypertensive (DS) rats with
end-stage heart failure. Decreased end-systolic elastance and
percent fractional shortening in failing heart were signiﬁcantly
ameliorated by olmesartan. Increased atherosclerosis and vas-
cular remodeling and ﬁbrosis factors such as procollagen types
I and III and ﬁbronectin expression in DS rats were inhibited
by olmesartan.
Effect of aliskiren, telmisartan, and torsemide on cardiac dysfunction in hypertensive rats 973Xu and Liu [37] investigated the effects of telmisartan, in
spontaneously hypertensive rats and reached the same results.
They stated that telmisartan signiﬁcantly decreased the pro-
duction of proinﬂammatory cytokines, myocardial apoptotic
markers and caspase-3 positive cells. Therefore, telmisartan
is beneﬁcial protection against heart failure and alternative
approach to treat cardiovascular disease. Telmisartan
enhanced nitric oxide release by activating the PI3K/Akt sys-
tem, phospho-p34 mitogen-activated protein kinase (AMPK).
Aliskiren had a more sustained effect on BP compared with
telmisartan [38]. The efﬁcacy of aliskiren and its long duration
of action, are largely attributed to its high potency for inhibi-
tion of human renin and its long half-life and tissue afﬁnity.
Moreover, aliskiren is retained in the kidney even after a 3-
week washout period [39].
Data of the present study also showed a cardio protective
effect of torsemide in L-NAME treated hypertensive rat model
as evident by signiﬁcant decrease in systolic blood pressure
compared to L-NAME group. The percentage of increase in
serum nitric oxide (NO) metabolites was 284% and the per-
centage decrease of collagen I and III genes expression were
84.4% and 86.1% respectively compared to L-NAME group.
The percentage inhibition of ﬁbrosis in torsemide treated
group compared to L-NAME group was 85%.
The ﬁndings of the present work are congruent with Yama-
naga et al. [40] who found a signiﬁcant fall in the systolic blood
pressure in the one-kidney, one-clip Goldblatt renal hyperten-
sive rat, greater in the torsemide group than in the furosemide
group. Lo´pez et al. [41] performed endomyocardial biopsies in
patients receiving either furosemide or torsemide. They found
a signiﬁcant improvement in all measured indicators of ﬁbrosis
among patients receiving torsemide, but not furosemide. They
attributed this to aldosterone blockade of torsemide.
Torsemide blocks the vasoconstrictor action of angiotensin
II in vitro. This action can be related to the ability of torsemide
to block the increase of Ca2+ induced by angiotensin II in vas-
cular smooth muscle cells [42]. Furthermore torsemide
increased intracellular cAMP and cGMP content in aorta of
renal hypertensive rat, but not furosemide [40].
The effects on the gene expression of cardiac contractile
proteins and collagen are signiﬁcantly different among diuret-
ics, which suggest that diuretics may have different cardiac
actions independent of their diuretic and antihypertensive
actions [43]. Based on this, it could be hypothesized that its
effects on cardiac ﬁbrosis occur by inhibiting the proﬁbrotic
actions of aldosterone [11].Conclusions
The three drugs aliskiren, telmisartan and torsemide decreased
blood pressure signiﬁcantly compared to L-NAME that started
from the 2nd week in aliskiren and telmisartan while from the
4th week in torsemide group. There is no signiﬁcant difference
between aliskiren and telmisartan in all the blood pressure
measurements . Meanwhile blood pressure of both aliskiren
and telmisartan was signiﬁcantly lower than torsemide starting
from 4th week. There was non-signiﬁcant difference between
the three treated groups NO levels. Collagen I and III was sig-
niﬁcantly decreased by the three drugs but the highest percent-
age of inhibition was in telmisartan treated group compared to
L-NAME. Comparing the percentage inhibition of ﬁbrosisbetween the three L-NAME treated groups, there was non-sig-
niﬁcant difference between telmisartan and torsemide treated
groups while both are superior to aliskiren.
Thus, further experimental studies are required to elucidate
the potential cardioprotective mechanisms of aliskiren, telmi-
sartan and torsemide, and clinical studies are required to assess
the cardioprotective effect of aliskiren, telmisartan and tor-
semide in treatment of heart failure.
Conﬂict of Interest
The authors have declared no conﬂict of interest.
References
[1] Lo´pez Salazar B, Ravassa Albe´niz S, Arias Guedo´n T, Gonza´lez
Miqueo A, Querejeta R, Dı´ez Martı´neza J. Altered ﬁbrillar
collagen metabolism in hypertensive heart failure. Current
understanding and future prospects. Rev Esp Cardiol
2006;59(10):1047–57.
[2] Ribeiro F, Alves AJ, Teixeira M, Ribeiro V, Duarte J, Oliveira J.
Endothelial function and atherosclerosis: circulatory markers
with clinical usefulness. Rev Portuguesa Cardiol
2009;28(10):1121–51.
[3] Radenkovic M, Stojanovic M, Potpara T, Prostran M.
Therapeutic approach in the improvement of endothelial
dysfunction: the current state of the art. BioMed Res Int
2013:12. Article ID 252158.
[4] Iusuf D, Henning RH, van Gilst WH, Roks AJ. Angiotensin-(1–
7). Pharmacological properties and pharmacotherapeutic
perspectives. Eur J Pharmacol 2008;585(2–3):303–12.
[5] Basile J. New therapeutic options in patients prone to
hypertension. A focus on direct Renin inhibition and
aldosterone blockade. Am J Med Sci 2009;337(6):438–44.
[6] Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN.
Aliskiren for geriatric lowering of systolic hypertension: a
randomized controlled trial. J Hum Hypertens 2009 [Epub
ahead of print].
[7] Staessen JA, Li Y, Richart T. Oral rennin inhibitors. Lancet
2006;368:1449–56.
[8] Gullapalli N, Bloch M, Basile J. Renin-angiotensin-aldosterone
system blockade in high-risk hypertensive patients: current
approaches and future trends. Ther Adv Cardiovasc Dis
2010;4(6):359–73.
[9] Zhong JC, Ye JY, Jin HY, Yu X, Yu HM, Zhu DL, et al.
Telmisartan attenuates aortic hypertrophy in hypertensive rats
by the modulation of ACE2 and proﬁlin-1 expression. Regul
Pept 2011;166:90–7.
[10] Remme W, Swedberg K. Task force for the diagnosis and
treatment of chronic heart failure, European Society of
Cardiology. Guidelines for the diagnosis and treatment of
chronic heart failure. Eur Heart J 2001;22:1527–60.
[11] Tsutamoto T, Sakai H, Wada A, Ishikawa C, Ohno K, Fujii M.
Torsemide inhibits transcardiac extraction of aldosterone in
patients with congestive heart failure. J Am Coll Cardiol
2004;44:2252–3.
[12] El-Mosallamy AE, Sleem AA, Abdel-Salam OM, Shafﬁe N,
Kenawy SA. Antihypertensive and cardioprotective effects of
pumpkin seed oil. J Med Food 2012;15(2):180–9.
[13] Gonzalez W, Fontaine V, Pueyo ME, Laquay N, Messika-
Zeitoun D, Philippe M, et al. Molecular plasticity of vascular
wall during NG-nitro-L-arginine methyl ester-induced
hypertension: modulation of proinﬂammatory signals.
Hypertension 2000;36(1):103–9.
[14] El-kharashi OA, Murad HAS, AbdAlaziz LF, Khalil1 AM,
Soliman AA. Potential renoprotective effects of eplerenone and
974 S.A. Sadek et al.captopril in L-Name-treated rats. Egypt J Basic Clin Pharmacol
2011;1(1):23–30.
[15] Benova M, Herichova I, Stebelova K, Paulis L, Krajcirovicova
K, Simko F, et al. Effect of L-NAME-induced hypertension on
melatonin receptors and melatonin levels in the pineal gland and
the peripheral organs of rats. Hypertens Res 2009;32(4):242–7.
[16] Nguelefack-Mbuyo P, Nguelefack T, Dongmo A, Afkir S,
Azebaze A, Dimo T, et al. Anti-hypertensive effects of the
methanol/methylene chloride stem bark extract of Mammea
africana in L-NAME-induced hypertensive rats. J
Ethnopharmacol 2008;117(3):446–50.
[17] Tomida T, Numaguchi Y, Nishimoto Y, Tsuzuki M, Hayashi Y,
Imai H, et al. Inhibition of COX-2 prevents hypertension and
proteinuria associated with a decrease of 8-iso-PGF2a
formation in LNAME- treated rats. J Hypertens
2003;21(3):601–9.
[18] Zhao Y, Bell D, Smith L, Zhao L, Devine A, McHenry E, et al.
Differential expression of components of the cardiomyocyte
adrenomedullin/intermedin receptor system following blood
pressure reduction in nitric oxide-deﬁcient hypertension. J
Pharmacol Exp Ther 2006;316(3):1269–81.
[19] Rossi MA, Colombini-Netto M. Chronic inhibition of NO
synthesis per se promotes structural intimal remodeling of the
rat aorta. J Hypertens 2001;19:1567–79.
[20] Hu C, Chang H, Hsu Y, Liu C, Chen H. Ventricular
hypertrophy and arterial hemodynamics following deprivation
of nitric oxide in rats. Life Sci 2005;78(2):164–73.
[21] Pinelli A, Trivulzio S, Tomasoni L, Bertolini B, Brenna S,
Bonacina E. Low nitric oxide values associated with low levels
of zinc and high levels of cardiac necrosis markers detected in
the plasma of rabbits treated with L-NAME. J Cardiovasc
Pharmacol 2001;37(3):310–6.
[22] Kobayashi N, Hara K, Watanabe S, Higashi T, Matsuoka H.
Effect of imidapril on myocardial remodeling in L-NAME-
induced hypertensive rats is associated with gene expression of
NOS and ACE mRNA. Am J Hypertens 2000;13(2):199–207.
[23] Zambrano S, Blanca AJ, Ruiz-Armenta MV, Miguel-Carrasco
JL, Are´valo M, Va´zquez MJ, et al. L-Carnitine protects against
arterial hypertension-related cardiac ﬁbrosis through
modulation of PPAR-c expression. Biochem Pharmacol
2013;85(7):937–44.
[24] Wood JM, Schnell CR, Cumin F, Menard J, Webb RL.
Aliskiren, a novel, orally effective renin inhibitor, lowers blood
pressure in marmosets and spontaneously hypertensive rats. J
Hypertens 2005;23:417–26.
[25] Rakusˇan D, Kujal P, Kramer HJ, Huskova Z, Vanourkova Z,
Vernerova Z, et al. Persistent antihypertensive effect of aliskiren
is accompanied by reduced proteinuria and normalization of
glomerular area in Ren-2 transgenic rats. Am J Physiol Renal
Physiol 2010;299(4):F758–66.
[26] Sun C-Y, Cherng W-J, Jian H-Z, Hsu H-H, Wu I-W, Hsu H-J,
et al. Aliskiren reduced renal ﬁbrosis in mice with chronic
ischemic kidney injury––beyond the direct renin inhibition.
Hypertens Res 2012;35:304–11.
[27] Whaley-Connell A, Habibi J, Rehmer N, Ardhanari S, Hayden
MR, Pulakat L, et al. Renin inhibition and AT(1)R blockade
improve metabolic signaling, oxidant stress and myocardial
tissue remodeling. Metabolism 2013;62(6):861–72.
[28] Lu H, Rateri DL, Feldman DL, Charnigo Jr RJ, Fukamizu A,
Ishida J, et al. Renin inhibition reduces hypercholesterolemia
induced atherosclerosis in mice. J Clin Invest 2008;118:984–93.[29] Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S,
Kitabata H. Renin inhibitor aliskiren improves impaired nitric
oxide bioavailability and protects against atherosclerotic
changes. Hypertension 2008;52:563–72.
[30] Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M,
Kvakan H, et al. Prorenin and renin-induced extracellular
signal-regulated kinase 1/2 activation in monocytes is not
blocked by aliskiren or the handle-region peptide.
Hypertension 2008;51:682–8.
[31] Rusai K, Jianxing C, Schneider R, Struijker-Boudier H, Lutz J,
Heemann U, et al. Renin inhibition mitigates anti-angiogenesis
in spontaneously hypertensive rats. J Hypertens 2011;29:
266–72.
[32] Casellas D, Herizi A, Artuso A, Mimran A, Jover B.
Candesartan prevents L-NAME-induced cardio-renal injury in
spontaneously hypertensive rats beyond hypotensive effects. J
Renin–Angiotensin–Aldosterone Syst 2001;2(1 suppl):S84–90.
[33] Wienen W, Schierok HJ. Effects of telmisartan,
hydrochlorothiazide and their combination on blood pressure
and renal excretory parameters in spontaneously hypertensive
rats. J Renin Angiotensin Aldosterone Syst 2001;2(2):123–8.
[34] Montanari A, Carra N, Perinotto P, Iori V, Fasoli E, Biggi A,
et al. Renal hemodynamic control by endothelin and nitric
oxide under angiotensin II blockade in man. Hypertension
2002;39:715–20.
[35] Mandarim-de-Lacerda CA, Pereira LMM. Effect of telmisartan
on preexistent cardiac and renal lesions in spontaneously
hypertensive mature rats. Histol Histopathol 2004;19:727–33.
[36] Fukushima H, Kobayashi N, Takeshima H, Koguchi W,
Ishimitsu T. Effects of olmesartan on apelin/APJ and Akt/
endothelial nitric oxide synthase pathway in Dahl rats with end-
stage heart failure. J Cardiovasc Pharmacol 2010;55(1):83–8.
[37] Xu L, liu Y. Administration of telmisartan reduced systolic
blood pressure and oxidative stress probably through the
activation of PI3K/Akt/eNOS pathway and NO release in
spontaneously hypertensive rats. Physiol Res 2013;62(4):351–9.
[38] Dusing R, Brunel P, Baek I, Baschiera F. Sustained blood
pressure-lowering effect of aliskiren compared with telmisartan
after a single missed dose. J Clin Hypertens (Greenwich)
2013;15(1):41–7.
[39] Boschmann M, Nussberger J, Engeli S, Danser AH, Yeh CM,
Prescott MF, et al. Aliskiren penetrates adipose and skeletal
muscle tissue and reduces renin–angiotensin system activity in
obese hypertensive patients. J Hypertens 2012;30(3):561–6.
[40] Yamanaga K, Uchida T, Kido H, Hayashi K, Watanabe M.
Torsemide, but not furosemide, increases intracellular cAMP
and cGMP content in the aorta of the renal hypertensive rat. J
Pharm Pharmacol 1992;44:64–5.
[41] Lo´pez B, Querejeta R, Gonza´lez A, Sa´nchez E, Larman M, Dı´ez
J. Effects of loop diuretics on myocardial ﬁbrosis and collagen
type I turnover in chronic heart failure. J Am Coll Cardiol
2004;43(11):2028–35.
[42] Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA,
Zalba G, et al. Torsemide inhibits angiotensin II induced
vasoconstriction and intracellular calcium increase in the aorta
of spontaneously hypertensive rats. Hypertension 1999;34(1):
138–43.
[43] Kim S, Hamaguchi A, Shinkawa T, Kato Y, Tsuchiya N, Miura
K, et al. Molecular effects of M17055, furosemide and thiazide
on cardiac hypertrophy of spontaneously hypertensive rats. J
Pharmacol Exp Ther 1996;279(2):983–90.
